Zhi Tong Cai Jing·2026-01-22 11:52Group 1 - The core announcement is that Fosun Pharma plans to spin off Fosun Antigen and list it on the Hong Kong Stock Exchange, with an initial offering size not exceeding 25% of the expanded total share capital post-issuance [1] - The proposed listing will target a global audience, including institutional investors, enterprises, and qualified domestic institutional investors, with a maximum of 15% over-allotment option granted to global coordinators or bookrunners [1] - Fosun Antigen operates independently within the group, focusing on vaccine research, production, and sales, utilizing various technological platforms [1] Group 2 - After the spin-off, Fosun Antigen will remain a subsidiary of the company, and its financial performance will still be reflected in the consolidated financial statements of the group [2] - There may be a short-term reduction in the net profit attributable to the company from Fosun Antigen, but long-term prospects indicate improved financing capabilities and enhanced operational scale and competitiveness [2] - The spin-off does not involve the issuance of new shares and will not affect the company's equity structure [2]